Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2004 1
2007 3
2010 1
2011 3
2015 1
2016 1
2018 1
2019 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Ketogenic Diet: An Effective Treatment Approach for Neurodegenerative Diseases.
Tao Y, Leng SX, Zhang H. Tao Y, et al. Curr Neuropharmacol. 2022 Nov 15;20(12):2303-2319. doi: 10.2174/1570159X20666220830102628. Curr Neuropharmacol. 2022. PMID: 36043794 Free PMC article. Review.
Finally, it discusses the common adverse effects of ketogenic therapy. Although the complete mechanism of the ketogenic diet in the treatment of neurodegenerative diseases remains to be elucidated, its clinical efficacy has attracted many new followers. The ketogenic diet …
Finally, it discusses the common adverse effects of ketogenic therapy. Although the complete mechanism of the ketogenic diet in the t …
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, Sathasivam S, Young CA. James E, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593746 Free PMC article. Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. ...The trial p …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegene …
Application and prospects of butylphthalide for the treatment of neurologic diseases.
Chen XQ, Qiu K, Liu H, He Q, Bai JH, Lu W. Chen XQ, et al. Chin Med J (Engl). 2019 Jun 20;132(12):1467-1477. doi: 10.1097/CM9.0000000000000289. Chin Med J (Engl). 2019. PMID: 31205106 Free PMC article. Review.
DATA SOURCES: Literature was collected from PubMed and Wangfang database until November 2018, using the search terms including "3-N-butylphthalide," "microcirculation," "mitochondria," "ischemic stroke," "Alzheimer disease," "vascular dementia," "Parkinson disease," "brain edema, …
DATA SOURCES: Literature was collected from PubMed and Wangfang database until November 2018, using the search terms including "3-N-butylpht …
Clinical features and differential diagnosis of flail arm syndrome.
Hübers A, Hildebrandt V, Petri S, Kollewe K, Hermann A, Storch A, Hanisch F, Zierz S, Rosenbohm A, Ludolph AC, Dorst J. Hübers A, et al. J Neurol. 2016 Feb;263(2):390-395. doi: 10.1007/s00415-015-7993-z. Epub 2015 Dec 24. J Neurol. 2016. PMID: 26705123
The aim of this study was to investigate typical clinical features of FAS with special regard to initial symptoms and differences to classical Charcot type amyotrophic lateral sclerosis (ALS). We retrospectively evaluated the clinical features of 42 FA …
The aim of this study was to investigate typical clinical features of FAS with special regard to initial symptoms and differences to classic …
Drug treatment for spinal muscular atrophy type I.
Wadman RI, van der Pol WL, Bosboom WM, Asselman FL, van den Berg LH, Iannaccone ST, Vrancken AF. Wadman RI, et al. Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD006281. doi: 10.1002/14651858.CD006281.pub5. Cochrane Database Syst Rev. 2019. PMID: 31825542 Free PMC article.
OBJECTIVES: To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy (SMA) type I. ...It is uncertain whether riluzole has any effect in patients with SMA type I, based on the limited available ev …
OBJECTIVES: To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy ( …
Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network meta-analysis of randomized controlled trials.
Sridharan K, Sivaramakrishnan G. Sridharan K, et al. J Clin Neurosci. 2018 May;51:12-17. doi: 10.1016/j.jocn.2018.02.011. Epub 2018 Feb 21. J Clin Neurosci. 2018. PMID: 29475576 Review.
Only botulinum toxin A and B were associated with significant therapeutic effects in Parkinson's disease. Benztropine and botulinum toxins A and B were observed to be effective in reducing sialorrhea associated with neurological disorders....
Only botulinum toxin A and B were associated with significant therapeutic effects in Parkinson's disease. Benztropine and botulinum t …
Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria?
Okita T, Nodera H, Shibuta Y, Nodera A, Asanuma K, Shimatani Y, Sato K, Izumi Y, Kaji R. Okita T, et al. J Neurol Sci. 2011 Mar 15;302(1-2):29-32. doi: 10.1016/j.jns.2010.12.007. Epub 2011 Jan 6. J Neurol Sci. 2011. PMID: 21215419
Eleven patients who met only AC electrophysiological criteria on the initial study subsequently met REEC electrophysiological criteria with the mean interval of 3.8 months. A higher percentage of bulbar-type ALS (83.3%) met AC than limb-onset ALS (43.4%) (P<0.05). FPs t …
Eleven patients who met only AC electrophysiological criteria on the initial study subsequently met REEC electrophysiological criteria with …
Salivary gland application of botulinum toxin for the treatment of sialorrhea.
Fuster Torres MA, Berini Aytés L, Gay Escoda C. Fuster Torres MA, et al. Med Oral Patol Oral Cir Bucal. 2007 Nov 1;12(7):E511-7. Med Oral Patol Oral Cir Bucal. 2007. PMID: 17978775 Free article. Review.
The most frequently treated diseases were infant cerebral palsy (30%), Parkinson's disease (20%) and amyotrophic lateral sclerosis (15%). Over half of the authors injected the product into the parotid glands, 9.5% into the submaxillary glands, and 38% into bo …
The most frequently treated diseases were infant cerebral palsy (30%), Parkinson's disease (20%) and amyotrophic lateral sc …
Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls.
Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Ellervik C, et al. Hepatology. 2007 Oct;46(4):1071-80. doi: 10.1002/hep.21885. Hepatology. 2007. PMID: 17828789
Finally, for amyotrophic lateral sclerosis, the odds ratio was 3.9 (1.2-13) for H63D/H63D versus wild type/wild type. ...CONCLUSION: In aggregate, clinically ascertained cases who are homozygous for the C282Y mutation are associated with a 4-11- …
Finally, for amyotrophic lateral sclerosis, the odds ratio was 3.9 (1.2-13) for H63D/H63D versus wild type/wild …
Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype.
Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Zetterberg H, et al. Eur J Neurol. 2007 Dec;14(12):1329-33. doi: 10.1111/j.1468-1331.2007.01972.x. Epub 2007 Sep 26. Eur J Neurol. 2007. PMID: 17903209
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative syndrome with familial and sporadic forms. ...NF-L levels were lower in SOD1 mutation-associated ALS compared with SOD1 wild-type (wt) ALS (P = 0.03). In conclusion, CSF NF-L levels may provide …
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative syndrome with familial and sporadic forms. ...NF-L levels we …
15 results